Gastric Cancer Clinical Trial
Official title:
A Pilot Study of Pre-rehabilitation in Neoadjuvant Patients With Gastric Cancer
In this study, patients with traditional neoadjuvant gastric cancer were used as controls to explore whether the triple pre-rehabilitation interventions of exercise, nutrition and psychology during the neoadjuvant period before surgery could improve the functional reserve of neoadjuvant gastric cancer patients and accelerate postoperative recovery.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | June 30, 2026 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Voluntarily participate in clinical research, fully understand and inform this research and sign the Informed Consent Form (ICF), and are willing to follow and have the ability to complete all experimental procedures; 2. The age when signing the informed consent form is 18 to 65 years old, male or female; 3. Advanced gastric adenocarcinoma patients diagnosed with clinical stage II-III by CT, MRI, gastroscope and pathology (based on the 8th edition UICC/AJCC staging); 4. The function of major organs is normal; 5. No history of gastric cancer surgery, chemotherapy or immunotherapy; 6. Not accompanied by systemic infection requiring antibiotic treatment; 7. After general examination, it is planned to undergo neoadjuvant immunotherapy and neoadjuvant chemotherapy followed by surgery; 8. No contraindications related to CT and MRI examinations; 9. ECOG score of 0-2 points; Exclusion Criteria: 1. The patient has a history of chemotherapy and immunotherapy in the past; 2. The patient cannot undergo CT or MRI scan, or has artifacts that cannot be assessed; 3. The patient refuses to participate in the study; 4. Patients who are going to undergo or have previously received organ or bone marrow transplantation; 5. The patient is pregnant, breastfeeding or unable to take appropriate contraceptive measures; 6. Patients with mental illness or related medical history, such as: the patient cannot understand the relevant requirements of this study; 7. Patients with human immunodeficiency virus (HIV) infection, active pulmonary tuberculosis or other severe, acute and chronic diseases that may increase the risk of participating in research and research drugs, and who are judged by the investigator to be unsuitable for participating in clinical research; 8. Other relevant factors are considered unsuitable for participating in the research by the researcher. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
The First Hospital of Jilin University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 6 minutes walking test | The maximum distance the patient can walk on an unimpeded hard surface in six minutes. | 1 month after surgery | |
Primary | Scored Patient-Generated Subjective Global Assessment score | Scored Patient-Generated Subjective Global Assessment(PG-SGA), PG-SGA consists of two parts: patient self-assessment and medical staff assessment. The specific contents include body weight, food intake, symptoms, activity and physical function, the relationship between disease and nutritional needs, metabolic needs, Physical examination and other 7 aspects, the first 4 aspects are evaluated by the patients themselves, and the last 3 aspects are evaluated by the medical staff. The overall evaluation includes qualitative evaluation and quantitative evaluation. Higher scores mean a worse outcome. | 1 month after surgery | |
Primary | DMSM score | Distress Management Screening Measure(DMSM), is an assessment tool recommended by the US National Comprehensive Cancer Network for screening the level and possible causes of psychological pain. The DMSM questionnaire consists of two parts: the first part is the Psychological Distress Thermometer (DT). The second part is the problem list (PL), which contains 36 factors.Higher scores mean a worse outcome. | 1 month after surgery | |
Secondary | Quality of life score QLQ-C30 | Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ-C30 ). | 3 month after surgery | |
Secondary | Quality of life score QLQ-STO22 | Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires ( QLQ-STO22). | 3 month after surgery | |
Secondary | Postoperative skeletal muscle index of the third lumbar spine plane. | Grip strength (Kg). | 3 month after surgery | |
Secondary | The rate of weight loss (=10%) . | The rate of weight loss (=10%) . | 3 month after surgery | |
Secondary | The incidence of sarcopenia. | The incidence of sarcopenia. | 3 month after surgery | |
Secondary | The ratio of actual ONS to recommended ONS. | The ratio of actual ONS to recommended ONS. | 3 month after surgery | |
Secondary | Albumin | Laboratory test: albumin (g/L) | 3 month after surgery | |
Secondary | Hemoglobin | Laboratory test: hemoglobin (g/L) | 3 month after surgery | |
Secondary | Prealbumin. | Laboratory test: prealbumin (g/L) | 3 month after surgery | |
Secondary | Incidence of adverse reactions during neoadjuvant therapy. | Incidence of adverse reactions during neoadjuvant therapy. | 1 month after surgery | |
Secondary | Completion rate of neoadjuvant therapy for gastric cancer | Number of completed courses/number of regimen courses | 1 month after surgery | |
Secondary | Surgery rate after neoadjuvant therapy for gastric cancer. | Surgery rate after neoadjuvant therapy for gastric cancer. | 1 month after surgery | |
Secondary | TRG grading after neoadjuvant therapy for gastric cancer. | TRG grading after neoadjuvant therapy for gastric cancer. | 1 month after surgery | |
Secondary | R0 resection rate | R0 resection rate | 1 month after surgery | |
Secondary | Postoperative complication rate of grade IIIa or above. | Postoperative complication rate of grade IIIa or above. | 3 month after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |